Dr AlHilali Consultant Clinical Oncologist
All articles
Understanding treatment Treatment decisions

Personalised mRNA cancer vaccines: what do melanoma results mean?

How personalised treatment vaccines differ from prevention vaccines, and how to interpret melanoma research without assuming a cure for every cancer.

Written and clinically reviewed by Dr AlHilali Consultant Clinical Oncologist

Published Clinical review

A personalised cancer vaccine is designed to help the immune system recognise features of a person's cancer. It is a treatment approach, not a vaccine that prevents every cancer from developing.

Research in melanoma is encouraging. Understanding who was treated, what the vaccine was compared with and which outcome improved matters more than the word “breakthrough”.

In this article

What makes it personalised?

Some approaches use information from the tumour to select abnormal features, called neoantigens, that the immune system might recognise. An mRNA vaccine provides instructions for making selected targets so that an immune response can be directed towards them.

This differs from vaccines against cancer-associated infections. It also differs from assuming that everyone with melanoma, or every person with another cancer, needs the same injection.

What did the melanoma study investigate?

In August 2026, Merck and Moderna reported positive phase III results for intismeran autogene, also known as V940, combined with pembrolizumab after surgery for specified stages of melanoma. The comparison was pembrolizumab alone, not no treatment. An October update reported presentation of phase III results at ESMO.

These are sponsor reports. They need to be read alongside the detailed trial results, rather than treated as independent treatment guidance. Earlier phase IIb findings are a separate dataset and must not be mixed with the phase III results.

Remaining free of recurrence is not the same as proving longer survival

Recurrence-free survival describes time without cancer returning or another event specified by the study. Overall survival asks a different question: how long participants live. A benefit in one endpoint does not, on its own, establish a benefit in the other.

Follow-up, side effects, confidence intervals and the patients included all affect interpretation. A result after melanoma surgery cannot simply be transferred to a different cancer or treatment setting. See what recurrence means.

What does this mean for someone seeking treatment?

Ask whether evidence applies to your cancer type and stage, whether the approach is available locally, and whether a suitable clinical trial exists. A positive trial, regulatory approval and routine NHS access are separate steps.

General information only. Do not delay established care or purchase a claimed universal cancer vaccine on the basis of a headline.

Sources

Continue reading